HZNP - Horizon Pharma plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Horizon Pharma plc

Connaught House
1st Floor 1 Burlington Road
Dublin 4
Ireland
353 1 772 2100
http://www.horizonpharma.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees1,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Timothy P. WalbertChairman, Pres & CEON/AN/A1967
Mr. Paul W. HoelscherExec. VP & CFON/AN/A1965
Mr. Barry J. MozeExec. VP & Chief Admin. Officer977.54kN/A1954
Ms. Irina KonstantinovskyExec. VP & Chief HR Officer514.53kN/A1970
Mr. Miles W. McHughChief Accounting Officer & Sr. VPN/AN/A1965
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Its primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. Horizon Pharma Public Limited Company has collaboration agreements with Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease; and HemoShear Therapeutics, LLC to discover and develop therapeutics for gout. The company was founded in 2005 and is headquartered in Dublin, Ireland.

Corporate Governance

Horizon Pharma plc’s ISS Governance QualityScore as of March 1, 2019 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.